Original research
Effects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosa-induced acute lung injury in a rat model
-
* Corresponding author: Teiji Sawa teiji@itsa.ucsf.edu
1 Department of Anesthesia and Perioperative Care, University of California, San Francisco, CA94143-0542, U.S.A
2 Department of Medicine, University of California, San Francisco, CA94143-0542, U.S.A
3 Cardiovascular Research Institute, University of California, San Francisco, CA94143-0542, U.S.A
4 Laboratoire de Recherche en Pathologie Infectieuse, EA2689, Lille, France
5 Department of Anesthesiology, School of Medicine, Yokohama City University, Yokohama 236-0004, Japan
6 Department of Anesthesiology, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan
7 InterMune, Inc., Brisbane, CA94010-1317, U.S.A
Journal of Immune Based Therapies and Vaccines 2003, 1:2 doi:10.1186/1476-8518-1-2
Published: 13 August 2003Abstract
Background
The effects of the murine monoclonal anti-PcrV antibody Mab166 on acute lung injury induced by Pseudomonas aeruginosa were analyzed in a rat model.
Methods
Lung injury was induced by the instillation of P. aeruginosa strain PA103 directly into the left lungs of anesthetized rats. One hour after the bacterial instillation, rabbit polyclonal anti-PcrV IgG, murine monoclonal anti-PcrV IgG Mab166 or Mab166 Fab-fragments were administered intratracheally directly into the lungs. The degree of alveolar epithelial injury, amount of lung edema, decrease in oxygenation and extent of lung inflammation by histology were evaluated as independent parameters of acute lung injury.
Results
These parameters improved in rats that had received intratracheal instillation of either rabbit polyclonal anti-PcrV IgG, murine monoclonal anti-PcrV IgG Mab166 or Mab166 Fab-fragments in comparison with the control group.
Conclusion
Mab166 and its Fab fragments have potential as adjuvant therapy for acute lung injury due to P. aeruginosa pneumonia.